LS Investment Advisors’s Corcept Therapeutics CORT Stock Holding History

LS Investment Advisors’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-9,239	Closed	-$220K	–	281
2021 Q1	$220K	Sell	9,239 -645	-7%	-$17.2K	0.01%	718
2020 Q4	$259K	Buy	+9,884	New	+$208K	0.01%	689
2020 Q3	–	Sell	-7,802	Closed	-$131K	–	942
2020 Q2	$131K	Hold	7,802	–	–	0.01%	893
2020 Q1	$93K	Hold	7,802	–	–	0.01%	917
2019 Q4	$94K	Buy	7,802 +2,610	+50%	+$36.3K	0.01%	1129
2019 Q3	$73K	Hold	5,192	–	–	﹤0.01%	1175
2019 Q2	$58K	Hold	5,192	–	–	﹤0.01%	1258
2019 Q1	$61K	Sell	5,192 -3,210	-38%	-$39.9K	﹤0.01%	1246
2018 Q4	$112K	Sell	8,402 -3,764	-31%	-$49.7K	0.01%	991
2018 Q3	$171K	Sell	12,166 -2,241	-16%	-$31.3K	0.01%	910
2018 Q2	$226K	Buy	14,407 +520	+4%	+$9.05K	0.01%	801
2018 Q1	$228K	Buy	+13,887	New	+$257K	0.01%	791

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

LS Investment Advisors's CORT Position: Q2 2021 in Review

LS Investment Advisors sold out of Corcept Therapeutics (CORT) in Q2 2021, closing a stake of 9,239 shares — an estimated $220K sold.

LS Investment Advisors first reported a position in CORT in Q1 2018 and held it in 12 quarters. The position peaked at $259K in Q4 2020. 199 funds tracked by Wall St. Rank hold CORT as of Q2 2021.

LS Investment Advisors reported no remaining Corcept Therapeutics position as of Q2 2021 after selling out during the quarter.
LS Investment Advisors sold 9,239 Corcept Therapeutics shares in Q2 2021, an estimated $220K.
LS Investment Advisors first reported a position in Corcept Therapeutics in Q1 2018 and held it in 12 quarters.
LS Investment Advisors's Corcept Therapeutics position peaked at $259K in Q4 2020.
199 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2021.

Based on LS Investment Advisors's 13F filing for Q2 2021, filed 11 Aug 2021.